Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | CFO | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 22,438 |
Reported balance
After 2026-08-17 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-17 · Grant · Acquired 22,438 · Balance 22,438 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 36,459 |
Reported balance
After 2026-08-17 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-08-17 · Grant · Acquired 36,459 · Balance 36,459 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F12: 36,459 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,011 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 4,011 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F8: 4,011 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,089 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 23,089 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F9: 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,807 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 9,807 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F10: 4,903 restricted stock units vest on 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. |
| Common StockSEC Table I · non-derivative | Direct | 170,183 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 170,183 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 167,328 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 167,328 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 40,536 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 40,536 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 45,220 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 45,220 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 2,332 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 2,332 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 45,923 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 45,923 F2: Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 32,417 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 32,417 F3: Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 37,632 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 37,632 F4: Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,062 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 24,062 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F6: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,420 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 29,420 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F7: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
F3: Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
F4: Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
F6: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F8: 4,011 restricted stock units vest on 8/15/2027.
F9: 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
F10: 4,903 restricted stock units vest on 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
F11: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029.
F12: 36,459 restricted stock units vest on 8/17/2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2023 Filed Aug 17, 2023 20:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 34,442 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016717 · form4.xml · derivative · entry 18 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,442 Underlying: Common Stock · 34,442 shares Expires 2030-08-15 F9 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 12,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016717 · form4.xml · derivative · entry 17 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,798 Underlying: Common Stock · 12,798 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:13 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 37,314 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022600 · form4a.xml · derivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,314 Underlying: Common Stock · 37,314 shares Expires 2030-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:13 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 13,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022600 · form4a.xml · derivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,865 Underlying: Common Stock · 13,865 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 12,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016038 · form4.xml · derivative · entry 10 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/5/2023, the Board of Directors certified vesting of 12,876 performance RSUs. F3 · derivative.expiration_date: On 8/5/2023, the Board of Directors certified vesting of 12,876 performance RSUs. Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 6,335 | $82.17 | $520,546.95 |
DisclosureSEC source: 0001062993-23-016038 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,561 Read SEC document |
| August 05, 2023 Filed Aug 8, 2023 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 12,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016038 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 11,305 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008781 · form4-08172022_020834.xml · derivative · entry 4 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,305 Underlying: Common Stock · 11,305 shares Expires 2029-08-15 F3 · derivative.exercise_date: Options to purchase 2,826 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026 and options to purchase 2,827 shares vest on 8/15/2024. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 8,479 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008781 · form4-08172022_020834.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,479 Underlying: Common Stock · 8,479 shares Expires 2029-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 21:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008781 · form4-08172022_020834.xml · derivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,728 Underlying: Common Stock · 2,728 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019662 · rdgdoc.xml · derivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/7/22, the Board of Directors certified vesting of 3,938 performance RSUs. F3 · derivative.expiration_date: On 8/7/22, the Board of Directors certified vesting of 3,938 performance RSUs. Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,938 | $382.97 | $742,195.86 |
DisclosureSEC source: 0001437749-22-019662 · rdgdoc.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,755 Read SEC document |
| August 07, 2022 Filed Aug 9, 2022 22:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019662 · rdgdoc.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 200 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · derivative · entry 9 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,389 Underlying: Common Stock · 200 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 200 | $525.10 | $105,020.00 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 200 | $125.05 | $25,010.00 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 8,822 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · derivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,589 Underlying: Common Stock · 8,822 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 943 | $528.55 | $498,426.80 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.16 to $528.995, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,433 | $527.50 | $755,903.06 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,698 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.14 to $528.00, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,880 | $526.50 | $1,516,321.44 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,131 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $526.105 to $527.08, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,566 | $525.61 | $1,874,318.48 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,011 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.10 to $526.09, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 8,822 | $125.05 | $1,103,191.10 |
DisclosureSEC source: 0000914190-21-000403 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 662 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0000914190-21-000394 · edgar.xml · derivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,411 Underlying: Common Stock · 662 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 662 | $525.23 | $347,704.05 |
DisclosureSEC source: 0000914190-21-000394 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.10 to $525.59, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2021 Filed Nov 1, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 662 | $125.05 | $82,783.10 |
DisclosureSEC source: 0000914190-21-000394 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,417 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 20:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $525.18 | $52,518.00 |
DisclosureSEC source: 0000914190-21-000394 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000359 · edgar.xml · derivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 7 | $509.17 | $3,564.19 |
DisclosureSEC source: 0000914190-21-000359 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,855 Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 9,993 | $507.22 | $5,068,600.49 |
DisclosureSEC source: 0000914190-21-000359 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,862 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $507.00 to $507.915, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000359 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 12 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 300 | $484.98 | $145,493.76 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 11 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,855 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.64 to $485.4475, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 300 | $483.62 | $145,085.01 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 10 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,155 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.59 to $483.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 300 | $481.61 | $144,481.50 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 9 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,455 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.49 to $481.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 700 | $480.66 | $336,462.49 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,755 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.23 to $481.185, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $480.70 | $48,070.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,455 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.70 to $480.70, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,300 | $479.96 | $623,953.72 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,555 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.69 to $480.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,800 | $478.58 | $861,444.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,855 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $478.25 to $479.12, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,200 | $477.69 | $2,484,001.52 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,655 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $477.20 to $478.13, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 3,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 15 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,383 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F11 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,665 | $481.82 | $802,230.30 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,855 Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 3,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 10,134 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 28 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,134 Underlying: Common Stock · 10,134 shares Expires 2028-08-06 F20 · derivative.exercise_date: Options to purchase 2,534 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 2,533 shares vest on each of 8/6/2024 and 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 7,600 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 27 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2028-08-06 F19 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,945 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 26 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,945 Underlying: Common Stock · 1,945 shares Expires not disclosed F9 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F19 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F19 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · derivative · entry 15 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $466.44 | $46,644.00 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 14 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 100 | $463.56 | $46,356.00 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 13 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,237 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 300 | $462.08 | $138,625.29 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 12 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,337 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $461.71 to $462.60, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.